Neovasc Inc
TSX:NVCN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Neovasc Inc
PP&E Net
Neovasc Inc
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neovasc Inc
TSX:NVCN
|
PP&E Net
$502.9k
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-10%
|
|
|
Profound Medical Corp
TSX:PRN
|
PP&E Net
$882k
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
18%
|
|
|
Theralase Technologies Inc
XTSX:TLT
|
PP&E Net
CA$503.9k
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
3%
|
|
|
MedMira Inc
XTSX:MIR
|
PP&E Net
CA$1.9m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
23%
|
|
|
O
|
Ondine Biomedical Inc
LSE:OBI
|
PP&E Net
CA$597k
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Conavi Medical Corp
XTSX:CNVI
|
PP&E Net
$1.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
Neovasc Inc
Glance View
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. The company is headquartered in Richmond British Columbia, British Columbia. The company went IPO on 2001-05-23. The firm develops, manufactures and markets products for the cardiovascular marketplace. The firm's products include the Neovasc ReducerTM (Reducer), for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary vasculature delivers an inadequate supply of blood to the heart muscle and the TiaraTM (Tiara), for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. Its wholly owned subsidiaries include Neovasc Medical Inc., Neovasc Tiara Inc., Neovasc (US) Inc., Neovasc Medical Ltd., B-Balloon Ltd., Neovasc GmbH, and Neovasc Management Inc.
See Also
What is Neovasc Inc's PP&E Net?
PP&E Net
502.9k
USD
Based on the financial report for Dec 31, 2022, Neovasc Inc's PP&E Net amounts to 502.9k USD.
What is Neovasc Inc's PP&E Net growth rate?
PP&E Net CAGR 10Y
-10%
Over the last year, the PP&E Net growth was -21%. The average annual PP&E Net growth rates for Neovasc Inc have been -30% over the past three years , -22% over the past five years , and -10% over the past ten years .
